Exagen Reiterates Full-Year Revenue Guidance Amid Record Growth
Exagen (XGN) has reaffirmed its full-year revenue guidance of $72 million to $75 million following a strong third quarter. CEO John Aballi noted that the company is currently experiencing a record year, driven by sustained performance across its diagnostic portfolio. Looking ahead, the company provided updates on its product pipeline, specifically noting that the launch for myositis testing is now targeted for early 2027. This strategic timeline sets the stage for long-term growth following the current fiscal period.
Tickers: $XGN